New PICCOLO trial analyses showed that mirvetuximab soravtansine achieved 52% response rates and 27-month overall survival in ...

During a live event, Heather L. McArthur, MD, MPH, discussed the TAILORx trial in node-negative hormone ...

Lynozyflic is one of two bispecific antibodies Regeneron hopes will lift its oncology business. Meanwhile, IGM is the latest struggling biotech to agree to a buyout deal from Concentra.

Industry veteran Catherine Owen Adams expects external innovation will be key to getting the brain-focused drug developer to “the next level.” ...

Datroway is used to treat an advanced form of non-small cell lung cancer in adults who had received prior treatment.

Rise in geriatric population; increase in healthcare expenditure; and increase in investments in R&D activities by various healthcare companies.” — Allied Market Research PORTLAND, IN, UNITED STATES, ...

AstraZeneca chief executive Pascal Soriot is considering moving the company's stock exchange listing from the UK to the US – ...

The Contrast Media Market is projected to grow at a CAGR of 5-6%. Key factors influencing the contrast media market include ...

A mum who has breast cancer is one of thousands of women who could be "missing out" on life-extending drugs because of the way they are assessed by the health service, a charity has warned. Breast ...

Thousands of women with advanced breast cancer could be denied life-extending drugs because of the "unfair" way they are ...